Fiche centre
Bryan Heart
Lincoln — United States
Essais liés4clinical trials
VilleLincolnlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04573660
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Maridebart cafraglutide | Insuffisance cardiaque | Phase 3 | NCT07037459 | MARITIME-HF — Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | RECRUITING |
| Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System | Insuffisance cardiaque | Non applicable | NCT05064709 | AIM HIGHer — Assessment of CCM in HF With Higher Ejection Fraction | RECRUITING |
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 4 | NCT06909565 | V-INTERVENTION — Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | RECRUITING |
| Coronary and peripheral stents | Maladie coronarienne | À vérifier | NCT04573660 | AV-MDR — Abbott Vascular Medical Device Registry | RECRUITING |